Published in AJNR Am J Neuroradiol on August 01, 2005
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol (2009) 1.08
Does high-field MR imaging improve cortical lesion detection in multiple sclerosis? J Neurol (2008) 1.05
Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment. Ther Adv Neurol Disord (2009) 1.02
Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx (2005) 0.98
Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurol (2012) 0.94
Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. Neuroimage Clin (2014) 0.91
Reliability and validity of neuropsychological screening and assessment strategies in MS. J Neurol (2007) 0.84
Correlations between MRI and Information Processing Speed in MS: A Meta-Analysis. Mult Scler Int (2014) 0.83
Statistical image analysis of longitudinal RAVENS images. Front Neurosci (2015) 0.79
Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology. Mult Scler (2015) 0.79
Overall Memory Impairment Identification with Mathematical Modeling of the CVLT-II Learning Curve in Multiple Sclerosis. Mult Scler Int (2012) 0.78
Short-latency afferent inhibition predicts verbal memory performance in patients with multiple sclerosis. J Neurol (2008) 0.76
Contribution of Gray and White Matter Abnormalities to Cognitive Impairment in Multiple Sclerosis. Int J Mol Sci (2016) 0.75
Brain Parenchymal Fraction in Healthy Adults-A Systematic Review of the Literature. PLoS One (2017) 0.75
Targeting Cognitive Impairment in Multiple Sclerosis-The Road toward an Imaging-based Biomarker. Front Neurosci (2017) 0.75
Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis. J Neurol (2016) 0.75
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Gray matter involvement in multiple sclerosis. Neurology (2007) 2.75
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc (2006) 2.58
The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol (2006) 2.47
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology (2006) 2.43
Acute disseminated encephalomyelitis in children. Pediatrics (2002) 2.03
Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci (2002) 1.91
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol (2007) 1.88
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol (2013) 1.83
Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol (2004) 1.82
Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci (2005) 1.76
Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol (2006) 1.76
Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage (2010) 1.71
Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging (2009) 1.70
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry (2013) 1.69
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Optical coherence tomography in multiple sclerosis. Lancet Neurol (2006) 1.65
Brain CT and MRI findings in 100 consecutive patients with intracranial tuberculoma. J Neuroimaging (2003) 1.64
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2010) 1.59
Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics (2007) 1.55
Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci (2004) 1.54
Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2014) 1.54
Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. J Neuroimaging (2003) 1.51
Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol (2011) 1.51
The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology (2013) 1.48
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol (2012) 1.46
Cerebellar mutism in pediatric acute disseminated encephalomyelitis. Pediatr Neurol (2010) 1.45
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.44
Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study. J Vasc Interv Radiol (2013) 1.43
Dynamics of neuronal sensitivity in visual cortex and local feature discrimination. Nat Neurosci (2002) 1.41
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (2007) 1.39
Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler (2004) 1.38
Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging (2006) 1.37
MRI in multiple sclerosis: what's inside the toolbox? Neurotherapeutics (2007) 1.34
Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology (2006) 1.33
The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis. J Neuroimaging (2011) 1.30
Nucleus basalis-enabled stimulus-specific plasticity in the visual cortex is mediated by astrocytes. Proc Natl Acad Sci U S A (2012) 1.30
Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol (2011) 1.29
Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci (2009) 1.28
Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage (2011) 1.27
T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging (2007) 1.26
Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging (2011) 1.24
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol (2006) 1.23
Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. Neuroimage (2004) 1.22
Cerebral venous thrombosis: analysis of a multicenter cohort from the United States. J Stroke Cerebrovasc Dis (2008) 1.19
Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging (2004) 1.18
Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. Radiology (2010) 1.18
The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage (2005) 1.16
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol (2013) 1.16
Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler (2011) 1.14
Smoking and disease progression in multiple sclerosis. Arch Neurol (2009) 1.13
Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis. Arch Neurol (2002) 1.12
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation (2011) 1.11
Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 1.11
Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci (2009) 1.11
The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc (2009) 1.10
Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol (2010) 1.10
Recent developments in imaging of multiple sclerosis. Neurologist (2011) 1.09
Multiple sclerosis medical image analysis and information management. J Neuroimaging (2005) 1.09
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol (2008) 1.07
A semiautomated measure of whole-brain atrophy in multiple sclerosis. J Neurol Sci (2003) 1.06
Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J Clin Exp Neuropsychol (2007) 1.05
Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J Neuropsychiatry Clin Neurosci (2002) 1.05
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis. Neuroimage (2009) 1.04
Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport (2003) 1.03
Central venous catheter-related blood stream infections: incidence, risk factors, outcome, and associated pathogens. J Cardiothorac Vasc Anesth (2004) 1.03
Approaches to normalization of spinal cord volume: application to multiple sclerosis. J Neuroimaging (2011) 1.02
Validity of the California Verbal Learning Test-II in multiple sclerosis. Clin Neuropsychol (2009) 1.02
MRI in multiple sclerosis: a review of the current literature. Curr Opin Neurol (2012) 1.01
Syncope and head CT scans in the emergency department. Emerg Radiol (2005) 1.01
Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem (2010) 1.01
Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord (2010) 1.01
Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging (2004) 1.01